Ramona Dadu
YOU?
Author Swipe
View article: Segmental Tracheal Resection for Thyroid Cancer: Perioperative Morbidity, Locoregional Control, and Survival
Segmental Tracheal Resection for Thyroid Cancer: Perioperative Morbidity, Locoregional Control, and Survival Open
Background Segmental tracheal resection is rarely needed for advanced thyroid cancer but is among the most complex, high‐risk thyroid surgeries. Methods Retrospective study of patients undergoing segmental tracheal resection for thyroid ca…
View article: Management of Retropharyngeal Lymph Node Metastases in Thyroid Cancer
Management of Retropharyngeal Lymph Node Metastases in Thyroid Cancer Open
Background Retropharyngeal lymph node (RPLN) metastases in thyroid cancer are rare, with optimal management underreported. Methods Retrospective study of consecutive thyroid cancer patients with RPLN metastases treated at MD Anderson Cance…
View article: Partial Laryngectomy for Thyroid Cancer: A Single Institution Case Series With Operative Techniques
Partial Laryngectomy for Thyroid Cancer: A Single Institution Case Series With Operative Techniques Open
Background Partial laryngectomy has been well described as a management option for T1–3 laryngeal squamous cell cancers. However, there are a few case reports of partial laryngeal surgery for locally advanced thyroid carcinoma. Methods Thi…
View article: Adjuvant pembrolizumab after upfront multimodal therapy for stage IVB Anaplastic Thyroid Cancer
Adjuvant pembrolizumab after upfront multimodal therapy for stage IVB Anaplastic Thyroid Cancer Open
Background ATC has historically been almost uniformly fatal. In patients with loco-regional disease (stage IVB), multimodal therapy (upfront surgery when feasible, radiation +/-concurrent chemotherapy) followed by observation is the curren…
View article: Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cells
Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cells Open
Patients with poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) face a much poorer prognosis than those with differentiated thyroid cancers. Around 25% of PDTCs and 35% of ATCs carry the BRAF V600E mutation, w…
View article: <i>NTRK</i> Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy
<i>NTRK</i> Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy Open
PURPOSE Neurotrophic tropomyosin receptor kinase ( NTRK ) fusions may act as an oncogenic driver in thyroid carcinomas. Given their low frequency, clinical, pathological, and molecular data on these patients and their responses to targeted…
View article: Recurrent Poorly Differentiated Thyroid Cancer Successfully Treated With Radiation and Immunotherapy
Recurrent Poorly Differentiated Thyroid Cancer Successfully Treated With Radiation and Immunotherapy Open
A 65-year-old patient presented with recurrent, locally advanced poorly differentiated thyroid cancer despite 2 neck surgeries, and with newly diagnosed brain and skull base metastases. He was treated with palliative stereotactic radiosurg…
View article: [<sup>18</sup>F]-FDG Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma following<i>BRAF</i>-Targeted Therapy
[<sup>18</sup>F]-FDG Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma following<i>BRAF</i>-Targeted Therapy Open
Preoperative FDG-PET noninvasively identifies lesions with residual high-risk pathologies following neoadjuvant BRAF-directed targeted therapy and immunotherapy for BRAF-mutated ATC. FDG-PET avidity may serve as an early prog…
View article: Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer
Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer Open
Despite an intensive treatment schedule, including AF and concurrent chemotherapy, classic radio-resistant and rapid Type A failures predominated; isolated extraneous dose failures were rare. While these findings support the IMRT and TV de…
View article: Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma Open
Importance Anaplastic thyroid carcinoma (ATC) is a rare and lethal cancer. Although progress has been made in recent years in patients with mutated BRAF tumors, those who respond initially eventually die of their disease; furthermore, ther…
View article: 7742 Clinical Outcomes of Thyroid Cancer Patients Enrolled in a Comprehensive Thyroid Cancer Survivorship Program
7742 Clinical Outcomes of Thyroid Cancer Patients Enrolled in a Comprehensive Thyroid Cancer Survivorship Program Open
Disclosure: M.A. Ruiz Santillan: None. J.L. Rollins: None. S. Lee-Kim: None. M.I. Hu: None. S.I. Sherman: None. J. Varghese: None. N.L. Busaidy: None. M. Cabanillas: None. R. Dadu: None. P.C. Iyer: None. A.K. Ying: None. S.G. Waguespack: N…
View article: MON-623 Real-Life Safety Monitoring for Patients with Advanced Thyroid Cancer on Targeted Therapy: A Quality Improvement Project
MON-623 Real-Life Safety Monitoring for Patients with Advanced Thyroid Cancer on Targeted Therapy: A Quality Improvement Project Open
S. Hamidi: None. L.E. Castellanos: None. S. Thosani: None. C.J. Best: None. S.I. Sherman: None. R. Dadu: None. A.K. Brinkman: None. M. Khoja: None. M.I. Hu: None. S.G. Waguespack: None. S.P. Weitzman: None. Background: Patients with advanc…
View article: Supplementary Figure S4 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S4 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Flow cytometry gating strategy in PBMC
View article: Supplementary Tables S1-S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Tables S1-S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Supplementary Table 1. Representativeness of Study Participants Supplementary Table 2. Adverse Events (regardless of attribution) Supplementary Table 3. Archival Tumor Biomarker Analyses in Cohort 1 Supplementary Table 4. Archival Tumor Bi…
View article: Supplementary Figure S6 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S6 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Myeloid subset frequency in peripheral blood before and on treatment
View article: Supplementary Figure S6 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S6 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Myeloid subset frequency in peripheral blood before and on treatment
View article: Supplementary Figure S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Increased HED and HLA diversity are not associated with improved PFS
View article: Supplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
NLR and MLR before and on treatment
View article: Data from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Data from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Purpose:Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting fur…
View article: Supplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
NLR and MLR before and on treatment
View article: Supplementary Figure S3 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S3 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Tumor density of CD8 T cells and myeloid subsets in DTC tumors
View article: Supplementary Figure S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Increased HED and HLA diversity are not associated with improved PFS
View article: Supplementary Figure S1 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S1 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Consort diagram
View article: Supplementary Figure S5 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S5 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Peripheral T cell subsets and response
View article: Supplementary Tables S1-S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Tables S1-S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Supplementary Table 1. Representativeness of Study Participants Supplementary Table 2. Adverse Events (regardless of attribution) Supplementary Table 3. Archival Tumor Biomarker Analyses in Cohort 1 Supplementary Table 4. Archival Tumor Bi…
View article: Supplementary Figure S5 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S5 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Peripheral T cell subsets and response
View article: Supplementary Figure S3 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S3 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Tumor density of CD8 T cells and myeloid subsets in DTC tumors
View article: Supplementary Figure S2 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S2 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
T cell and myeloid cell staining in DTC tumors
View article: Supplementary Figure S4 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Figure S4 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Flow cytometry gating strategy in PBMC
View article: Data from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Data from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers Open
Purpose:Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting fur…